In ovarian cancer, knockdown of HSP60 suppresses pathways related to OXPHOS and alters metabolic pathways to allow accumulation of adenine, which activates the adenine-AMPK pathway, suppresses the mammalian target of rapamycin (mTOR) pathway, and inhibits cancer progression [178]. This evidence concerns the gene HSPD1 and ovarian cancer.